

Ref No. NLL/CS/2017- 199

Date: 11.11.2017

1. National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Financial Results.

Ref: Compliance Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sir's,

The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone Financial results for the quarter and half year ended September 30, 2017 which are enclosed herewith along with the Limited Review Report of the Auditors thereon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Nectar Lifesciences Limited

Dinesh Dua
Chief Executive Officer & Director

To Whomsoever It May Concern

We have reviewed the accompanying statement of unaudited financial results of **Nectar Lifesciences Limited** for the quarter ended **September 30, 2017** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI(Listing obligation and Disclosure Requirements) Regulation 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim financial information performed by Independent Auditors of the Entity* issued by the Institute of Chartered Accountant of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Ashwani K. Gupta & Associates
Chartered Accountants
Firm Regn. No. 003803N



(ASHWANI KUMAR GUPTA)

Partner

M. No. 082808

Place: Chandigarh

Date: 11.11.2017

NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab, CIN: L24232PB1995PLC016664

Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email: cs@neclife.com, Website : www.neclife.com

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30.09.2017

(Rs in Lacs)

S. No	PARTICULARS	Quarter ended			Half Year ended		Year ended
		30-09-2017	30-06-2017	30-09-2016	30-09-2017	30-09-2016	31-03-2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income from Operations						
	Net Sales (inclusive of excise duty/GST)	48,013.29	34,146.11	44,160.31	82,159.40	81,782.63	174,362.70
	Other operating Income	-	4.30	-	4.30	26.10	29.19
II	Other Income	131.43	132.99	127.46	264.42	273.11	2,236.53
III	Total Income (I + II)	48,144.72	34,283.40	44,287.77	82,428.12	82,081.84	176,628.42
IV	Expenses						
	(a) Cost of Materials consumed	28,756.85	20,848.33	29,309.16	49,605.18	52,257.42	113,333.22
	(b) Purchase of Stock in Trade	364.93	331.29	290.78	696.22	521.97	1,250.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	979.37	(312.02)	(641.52)	667.35	(123.08)	833.71
	(d) Excise Duty/GST	4,683.67	2,369.13	2,694.49	7,052.80	4,899.14	10,028.77
	(e) Employee benefits expense	1,994.25	1,934.89	2,089.28	3,929.14	4,071.45	7,923.63
	(f) Finance costs	2,758.35	2,675.55	2,910.95	5,433.90	5,796.03	11,741.27
	(g) Depreciation and amortisation expense	1,649.76	1,545.83	1,494.71	3,195.59	3,001.83	6,225.10
	(h) Other expenses	4,771.28	3,723.68	4,263.95	8,494.96	8,328.09	18,571.47
	Total Expenses (IV)	45,958.46	33,116.68	42,411.80	79,075.14	78,752.85	169,907.17
V	Profit/(loss) before exceptional items and tax (III- IV)	2,186.26	1,166.72	1,875.97	3,352.98	3,328.99	6,721.25
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit from ordinary activities before tax (V - VI)	2,186.26	1,166.72	1,875.97	3,352.98	3,328.99	6,721.25
VIII	Tax Expense	299.13	127.68	264.30	426.81	487.16	1,207.89
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	1,887.13	1,039.04	1,611.67	2,926.17	2,841.83	5,513.36
	Other Comprehensive Income						
	Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	2.04
	Total Other Comprehensive Income, (Net of Tax)	-	-	-	-	-	2.04
	Total Comprehensive Income for the period	1,887.13	1,039.04	1,611.67	2,926.17	2,841.83	5,515.41
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)						
	a) Basic	0.84	0.46	0.72	1.30	1.27	2.46
	b) Diluted	0.84	0.46	0.72	1.30	1.27	2.46



Statement of Standalone Assets and Liabilities

Particulars	As At	
	30-Sep-17 Unaudited	31-Mar-17 Audited
ASSETS		
Non-current assets		
Property, plant and equipment	81,550.56	82,379.65
Capital work-in-progress	10,173.12	10,211.39
Intangible assets	4,871.69	5,744.29
Financial assets		
Investments	60.03	60.03
Other financial assets	431.02	431.02
Other non-current assets	9,887.23	9,411.23
Current assets		
Inventory	89,091.79	85,412.96
Financial assets		
Investments	50.83	40.83
Trade receivables	53,206.81	50,344.12
Cash and cash equivalents	137.67	1,281.04
Loans	44.19	31.68
Other financial assets	7,447.38	6,444.00
Other current assets	7,526.42	6,312.73
Total Assets	264,478.74	258,104.97
EQUITY AND LIABILITIES		
Equity		
Equity share capital	2,242.61	2,242.61
Other equity	101,356.26	98,430.10
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	13,792.41	16,379.95
Other financial liabilities	1,858.45	1,878.21
Other Non-Current Liability	91.46	92.08
Provisions	849.21	849.21
Deferred tax liabilities (net)	10,433.65	10,366.90
Current liabilities		
Financial liabilities		
Borrowings	64,569.59	63,034.09
Trade payables	54,560.02	52,809.78
Other financial liabilities	11,340.50	10,030.80
Other current liabilities	1,221.60	657.27
Provisions	149.26	122.85
Current tax liabilities (net)	2,013.72	1,211.12
Total equity and liabilities	264,478.74	258,104.97



For Nectar Lifesciences Limited

Dinesh Dua

Chief Executive Officer & Director